CancerVisit

Missed the bladder cancer sessions at #GU26? @CParkMD of @Norton_Health has you covered! ✅ In the recap below, Dr Park breaks down the 2 most impactful presentations in urothelial cancer from this year's meeting: 📊-Pivotal data on perioperative EV + pembro from EV-304/KEYNOTE-B15 🧬-utDNA/ctDNA analysis of NIAGARA Watch the video to learn just why these studies are so important for practice. 🎥👇 #oncology

Important data in IO era. Should have a low threshold to stop pemetrexed maintenance for pts with stable or responding advanced lung adeno carcinoma. #lcsm

On the cover this week, a major meta-analysis assesses the adverse effects attributed to statin therapy in product labels. 🏷️ The study found that almost all side effects on statin labels are not caused by statins. The authors call for the labels to be updated. Read this & more: spkl.io/6015AtvkH

Stop treating #pCR as the definitive finish line. Recent data (doi.org/10.1158/2767-9…) confirms that #ctDNA status after neoadjuvant therapy (#NAT) is a more precise prognostic indicator than #pCR. In HER2+ cohorts, patients who remained ctDNA+ after surgery were 5.5x more likely to recur, regardless of whether they achieved #pCR. The Reality Check: Prognostic vs. Predictive: We can identify high-risk patients (Prognostic), but we haven't proven yet that changing therapy based on that signal alone improves survival (Predictive). The "Low-Shedder" Floor: Especially in ER+ disease, a negative draw may just be the assay’s sensitivity limit. We can’t safely de-escalate yet. Clinical Mandate: Use ctDNA to prioritize high-risk surveillance and trial enrollment. Don’t go rogue on SOC until we have prospective utility data. #BCSM #OncTwitter #precisiononcology @SABCSSanAntonio @oncodaily